281 related articles for article (PubMed ID: 34257556)
21. Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations.
Chapel DB; Husain AN; Krausz T
Mod Pathol; 2019 Mar; 32(3):376-386. PubMed ID: 30315275
[TBL] [Abstract][Full Text] [Related]
22. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
23. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.
Louw A; Lee YCG; Acott N; Creaney J; van Vliet C; Chai SM
Cytopathology; 2022 Jan; 33(1):84-92. PubMed ID: 34033161
[TBL] [Abstract][Full Text] [Related]
25. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
Kushitani K; Amatya VJ; Mawas AS; Miyata Y; Okada M; Takeshima Y
Pathobiology; 2016; 83(1):33-40. PubMed ID: 26735863
[TBL] [Abstract][Full Text] [Related]
26. Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas.
Amacher V; Bode PK; Moch H; Lenggenhager D; Vrugt B
Acta Cytol; 2023; 67(4):444-450. PubMed ID: 36889303
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
28. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma.
Lynggård LA; Panou V; Szejniuk W; Røe OD; Meristoudis C
J Am Soc Cytopathol; 2022; 11(6):385-393. PubMed ID: 35945149
[TBL] [Abstract][Full Text] [Related]
30. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
31. Development of mesothelioma in situ and its progression to invasive disease observed in a patient with uncontrolled pleural effusions for 15 years.
Hidaka K; Takeda T; Kinoshita Y; Nabeshima K; Tamiya S; Yoshikawa Y; Tsujimura T
Pathol Int; 2020 Dec; 70(12):1009-1014. PubMed ID: 32956524
[TBL] [Abstract][Full Text] [Related]
32. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
[TBL] [Abstract][Full Text] [Related]
33. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
34. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
35. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
[TBL] [Abstract][Full Text] [Related]
36. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
37. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M
Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100
[TBL] [Abstract][Full Text] [Related]
38. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
Hiroshima K; Wu D; Hamakawa S; Tsuruoka S; Ozaki D; Orikasa H; Hasegawa M; Koh E; Sekine Y; Yonemori Y; Nabeshima K; Tsuji S; Miyagi Y; Imai K
Diagn Cytopathol; 2021 May; 49(5):622-632. PubMed ID: 32441895
[TBL] [Abstract][Full Text] [Related]
39. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
[TBL] [Abstract][Full Text] [Related]
40. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
